UNSPSC 51314366: Dextromethorphan/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314366 Dextromethorphan/phenylephrine/pyrilamine is a Commodity code that encompasses over-the-counter and prescription pharmaceutical products supplied to state and local health agencies, public health departments, and cooperative purchasing alliances. State and local governments procure these medications through direct-to-vendor purchasing, cooperative agreements with authorized wholesalers, and community health initiatives. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. The work involves supplying pharmaceutical products with specific National Drug Codes (NDCs), managing inventory through authorized distribution channels, and ensuring compliance with Drug Supply Chain Security Act (DSCSA) requirements, current Good Manufacturing Practices (cGMP) certification, and FDA regulations including minimum shelf-life standards.

Recent activity spans Florida, Texas, and Minnesota, with representative solicitations including Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and fixed-fee pricing on a two-year initial term with one-year renewal option; Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs and vendor capacity for negotiated net pricing models outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with awards effective July 1, 2026, evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, requiring vendors to maintain $5 million commercial general liability and cGMP certification.